A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.

Trial Profile

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs NN 9030 (Primary) ; Liraglutide
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 23 Aug 2016 Status changed from recruiting to completed.
    • 11 Dec 2015 Planned number of patients changed from 160 to 176, according to ClinicalTrials.gov record.
    • 22 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top